OPKO Health, Inc. OPK continues to benefit from lucrative RAYALDEE and BioReference platforms, solid focus on research and development (R&D), and optimistic outlook for third-quarter 2019. However, operating losses remain concerning.
Shares of OPKO Health have lost 46.8% against the industry’s growth of 19.7% on a year-to-date basis. Meanwhile, the S&P 500 Index rallied 22.8% in the same timeframe.
The company, with a market capitalization of $1.07 billion, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. It anticipates earnings to improve 12% in the next five years.
Let’s delve deeper and analyze the factors that substantiate why it is alright to hold on to the Zacks Rank #3 (Hold) stock for now.
What’s Deterring the Stock?
OPKO Health has an infamous record of incurring huge operating losses. To date, the company has generated limited revenues from pharmaceutical operations in the United States, Chile, Mexico, Israel, Spain and Ireland.
In the third quarter of 2019, OPKO Health incurred an operating loss of $39 million. For the fourth quarter, the company projects operating loss between $42 million and $69 million (including $25 million of non-cash, depreciation and amortization).
What’s Favoring the Stock?
Lucrative prospects in RAYALDEE and BioReference platforms have been providing a competitive edge to OPKO Health in the MedTech Industry. RAYALDEE has been witnessing a decent momentum, courtesy of successful efforts from the sales team.
The company expects the BioReference R&D pipeline to increase throughout 2019, with improving cash flows from Bio-Reference and RAYALDEE.
OPKO Health’s focus on R&D is a positive factor. The company’s strong commitment toward innovation led to product introductions, improvement in existing products, and product-line expansion. Moreover, the commitment resulted in the enhancement of R&D facilities and procurement of new equipment for the same.
Per management, the company will continue to make solid investments in R&D programs throughout 2019. OPKO Health projects R&D expenses of $28-$31 million for the fourth quarter.
Strong outlook for fourth-quarter 2019 buoys optimism about the stock. For the quarter, management anticipates revenues from Services between $165 million and $175 million (excluding revenues from 4kscore from Medicare beneficiaries). The company expects Product revenues of $25-$29 million, including $8-$9 million revenues from RAYALDEE.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $895.6 million, indicating a 9.6% decline from the year-ago period’s reported number. The same for earnings stands at a loss of 43 cents per share.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Conmed Corporation CNMD, Cardinal Health, Inc CAH and DENTSPLY SIRONA Inc XRAY, each currently carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Conmed has a long-term earnings growth rate of 17%.
Cardinal Health has a long-term earnings growth rate of 6.2%.
DENTSPLY SIRONA has a long-term earnings growth rate of 11.6%.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report
CONMED Corporation (CNMD) : Free Stock Analysis Report
Cardinal Health, Inc. (CAH) : Free Stock Analysis Report
To read this article on Zacks.com click here.